8-K: Calidi Biotherapeutics Warrants Face Delisting from NYSE American Due to Low Trading Price

Calidi Biotherapeutics' warrants are set to be delisted from the NYSE American due to their low trading price, while the company's common stock will continue to trade on the exchange.

Summary

• Calidi Biotherapeutics received notice from the NYSE that its warrants, trading under the symbol CLDI WS, are no longer suitable for listing due to their low trading price.
• The NYSE Regulation has initiated proceedings to delist the warrants.
• Each warrant is exercisable for 1/10th of a share of common stock at an exercise price of $115.00 per whole share.
• Trading of the warrants will be suspended immediately.
• The company has the right to appeal the delisting decision.
• The delisting of the warrants does not affect the trading of Calidi's common stock, which will continue on the NYSE American under the ticker symbol CLDI.
• The company issued a press release on October 18, 2024, announcing the receipt of the delisting notice.

Sentiment

Score: 3

Explanation: The delisting of warrants is a negative event, indicating a lack of investor confidence in the warrants. While the common stock is unaffected, the overall sentiment is negative.

Positives

• The delisting only affects the warrants and not the common stock, which will continue to trade on the NYSE American.
• The company has the right to appeal the delisting decision.

Negatives

• The warrants are being delisted due to their low trading price, indicating a lack of investor confidence in the warrants.
• Trading of the warrants will be suspended immediately.

Risks

• The delisting of the warrants could negatively impact investor sentiment towards the company.
• The low trading price of the warrants may reflect underlying concerns about the company's performance or prospects.
• There is a risk that the company's appeal against the delisting may not be successful.

Future Outlook

The company's future outlook is subject to risks and uncertainties, including the ability to raise sufficient capital and the success of clinical trials. The company has made forward-looking statements regarding upcoming milestones, planned clinical trials, and the safety and efficacy of its therapeutic candidates, but these are subject to change.

Management Comments

• The company has made no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

Industry Context

This delisting notice highlights the challenges faced by smaller biotechnology companies, particularly those with warrants trading at low prices. It is not uncommon for warrants to be delisted if they fail to maintain a minimum trading price, which can impact investor confidence.

Comparison to Industry Standards

• Delisting of warrants due to low trading price is not uncommon in the biotech industry, especially for smaller companies.
• Many biotech companies with warrants trading at low prices face similar delisting risks.
• The delisting of warrants does not necessarily reflect the performance of the underlying common stock, which in this case will continue to trade on the NYSE American.

Stakeholder Impact

• Shareholders holding warrants will be impacted by the delisting and suspension of trading.
• Shareholders holding common stock are not directly impacted by the delisting of the warrants.

Next Steps

• The company may appeal the delisting decision.
• The NYSE will apply to the SEC to delist the warrants upon completion of all applicable procedures.

Key Dates

Keywords

delisting, warrants, NYSE American, CLDI WS, low trading price, Calidi Biotherapeutics, common stock, CLDI